Ampio Pharma Begins Patient Dosing In AP-019 Phase II Study Of Inhaled Ampion In Covid-19 Respiratory Distress

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced randomization and dosing of patients in its multi-center AP-019 phase II clinical trial, using inhaled Ampion in the treatment of respiratory distress due to Covid-19, is underway.“We saw strong, positive results in our phase I trial, reducing all-cause mortality in Covid-19 respiratory distress by 78%. If this phase II study further confirms the efficacy results seen in our phase I study, I can envision moving forward quickly with an application for Emergency Use Authorization for Ampion in treating patients suffering from respiratory distress due to Covid-19,” said Michael Macaluso, President and CEO of Ampio.As an immunomodulatory agent with anti-inflammatory effects, Ampion interrupts the hyperactive immune response associated with Covid-19 and may improve the clinical outcome for patients suffering from its complications.The company initiated the AP-019, double-blind, placebo-controlled phase II trial, utilizing inhaled Ampion following the strong top-line results achieved from its AP-014 phase I trial. On April 27, 2021, the company reported the earlier phase I study not only met its primary endpoint of safety and tolerability, but top-line results also showed that Ampion reduced all-cause mortality in patients suffering from Covid-19 respiratory distress by 78% over the Standard of Care (SOC). Specifically, mortality in the SOC group was 24%, while in the group treated with Ampion, mortality was only 5%.“Roughly 300 people per day are dying of Covid-19 in the US,” Macaluso continued, “with a seven-day average of 10,000 per day worldwide. There is a perception the vaccine rollout has ended the pandemic, but Covid-19 is likely to remain a concern for some time to come, and physicians need tools to treat it.”Ampio also recently received approval from the FDA to expand the AP-019 study to India, which has recently seen a dramatic surge in Covid-19 cases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!